425 related articles for article (PubMed ID: 6222288)
1. A case for concern?
Gartland A
Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
[TBL] [Abstract][Full Text] [Related]
2. Depo-Provera: just another contraceptive?
Jones M
Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094
[TBL] [Abstract][Full Text] [Related]
3. Depo Provera: still controversial.
Wren LM
Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
[TBL] [Abstract][Full Text] [Related]
4. The use of Depo-Provera in East London.
Savage W
Fertil Contracept; 1978 Jul; 2(3):41-7. PubMed ID: 12260723
[TBL] [Abstract][Full Text] [Related]
5. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
Richard BW; Lasagna L
Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
[TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
[TBL] [Abstract][Full Text] [Related]
7. Depo Provera: a profile of current users.
Jarman H; Kovacs GT; Westcott M
Aust N Z J Obstet Gynaecol; 1990 Feb; 30(1):74-6. PubMed ID: 2140675
[TBL] [Abstract][Full Text] [Related]
8. Depo-Provera: a critical analysis.
Minkin S
Women Health; 1980; 5(2):49-69. PubMed ID: 6451987
[TBL] [Abstract][Full Text] [Related]
9. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
10. Extracts from the report on the Joint IGCC/IFRP East and South East Asia Seminar on Regional Fertility Research.
Mcdaniel EB
IGCC News; 1980 Jan; 5(3):1-4. PubMed ID: 12179403
[TBL] [Abstract][Full Text] [Related]
11. Depo-Provera--ethical issues in its testing and distribution.
Potts M; Paxman JM
J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
[TBL] [Abstract][Full Text] [Related]
12. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
13. FDA board investigates Depo-Provera safety.
Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
[TBL] [Abstract][Full Text] [Related]
14. The Depo-Provera public hearing.
Dening FC
Midwives Chron; 1983 Jul; 96(1146):246. PubMed ID: 6225940
[No Abstract] [Full Text] [Related]
15. Medroxyprogesterone acetate [Depo Provera] injections. Development of striae.
Gupta M
Br J Fam Plann; 2000 Apr; 26(2):104-5. PubMed ID: 10773604
[TBL] [Abstract][Full Text] [Related]
16. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
Polaneczky M; Liblanc M
J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
[TBL] [Abstract][Full Text] [Related]
17. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
18. FDA gives final approval to Depo amid concerns over safety, cost and coercion.
Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620
[TBL] [Abstract][Full Text] [Related]
19. Testing times for women in body lab.
Bacon W
Lamp; 1983 May; 40(3):38-40. PubMed ID: 6228701
[TBL] [Abstract][Full Text] [Related]
20. Not FDA-approved, but experts recommend Depo-Provera.
Contracept Technol Update; 1992 Jan; 13(1):1-7. PubMed ID: 12343458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
